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line characteristics: Age, Sex, and BMI. We used existing literature and public da-
tasets to estimate the parameters of the model. For the BMI trajectory, we utilized
existing literature on pooled databases of the individuals’ BMI over time. For the
probability of death, we constructed life tables by estimating the 5-year probability
of death using a logistic regression model using data from the National Health
Institute Survey linked with National Death Index (NHIS-NDI) between 1997 and
2005. For costs and QALYs, we useMedical Expenditure Panel Survey Panels 6-10 to
estimate hedonic linear regressions in each period. Costs and QALYs were dis-
counted at 3%. RESULTS: In the base case— for a 45 year-old female—the expected
age of death for baseline BMI of 25, 35, or 45 was 83, 80, and 77, respectively. The
projected difference in discounted lifetime healthcare costs between this non-
obese (BMI 25) person and someone BMI 45 is about $26,000. If the loss inQALYs
were valued at $100,000/QALY, the net economic value loss is projected at $271,000.
CONCLUSIONS: Obesity is associated with higher medical costs, lower quality of
life, and reduced life expectancy. The societal cost of delivering effective weight
loss interventions to obese Americans should be considered in the context of these
lifetime outcomes.
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OBJECTIVES: ITP is characterized by reduced platelet counts and increased risk of
bleeding. Romiplostim, a first-in-class thrombopoietin mimetic, safely increases
and sustains platelet counts in most adult patients with chronic ITP for as long as
needed, while reducing the need for concurrent and emergency medications. We
evaluated treatment costs per overall platelet response with romiplostim  con-
current treatment vs. placebo  concurrent treatment in chronic adult ITP, from a
Public Mexican Healthcare perspective.METHODS: Overall response, defined as 
4 weekly platelet responses (50x109/L ) from weeks 2 to 25, was derived from two
randomized parallel trials with splenectomised and non-splenectomised patients
over period of 24 weeks. All patients were allowed to enter on concurrent ITP
medication (danazol, corticosteroids, azathioprine) and receive rescue medication
(eg, intravenous immunoglobulin). Treatment costs included intervention, rescue
medication and management of bleeding-related events during one year period.
Unitary costs were obtained from the 2010 Official Price List of the Public Health-
care System in Mexico ($MXP). Mean treatment cost per response was calculated
for splenectomized and non-splenectomized patients. RESULTS:Cost per response
was lower for romiplostim compared to placebo. Overall response rates were 79%
for romiplostim and 0% for placebo in splenectomized patients and 88% for romi-
plostim vs. 14% for placebo in non-splenectomized patients. Mean treatment costs
were MXP$574,580 for romiplostim and MXP$301,218 for placebo in splenecto-
mized patients and MXP$402,083 for romiplostim and MXP$180,692 for placebo in
non-splenectomized patients. Cost per response were MXP$727,317 for romiplos-
tim and infinite cost per response for placebo in splenectomized patients and
MXP$456,912 for romiplostim and MXP$1,290,655 for placebo in non-splenecto-
mized patients. Themain cost-offsetswere due to reduced immunoglobulin rescue
use. CONCLUSIONS: Given the limited number of effective therapies in ITP, romi-
plostimdemonstrates an important and cost-efficient option for both non-splenec-
tomised and splenectomised patients for the Mexican Public Healthcare System.
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OBJECTIVES: Thrombocytopenia may prevent chronic hepatitis C (CHC) patients
from initiating or maintaining anti-viral therapy. Eltrombopag is a thrombopoietin
receptor agonist currently undergoing phase III trials for treatment of CHC-related
thrombocytopenia. This study examines the cost-effectiveness of eltrombopag in
CHC patients with cirrhosis and thrombocytopenia.METHODS: A two-part model
was developed to estimate quality adjusted life years(QALYs) gained with and
without eltrombopag for a hypothetical population of 50-year-old, white,male CHC
patientswith thrombocytopenia and cirrhosiswho are otherwise eligible to initiate
anti-viral therapy. A decision tree followed the first 48 weeks of anti-viral therapy
for patients receiving eltrombopag (30,50,or 75mg dose) versus a placebo con-
trolled, wait-and-see (W&S) strategy. Lifetime outcomes of anti-viral therapy suc-
cess or failure were projected using a Markov model. Eltrombopag probabilities
were taken from a Phase II trial; other probabilities and costs were derived from
published literature. Model outcomes are presented as incremental cost effective-
ness ratios (ICERs). A probabilistic sensitivity analysis was performed to analyze
parameter uncertainty. RESULTS: Successive eltrombopag dosing strategies were
associated with incremental increases in cost and QALYs. All strategies were cost-
effective at a threshold of $50,000/QALY gained. The 75mg strategy weakly domi-
nated the 50mg and 30mg strategies and had an ICER of $27,496 compared to the
W&S strategy. Results were robust to variation among input parameters.
CONCLUSIONS: The results of this study support the use of eltrombopag as a
cost-effective option in CHC patients with thrombocytopenia. Patients on eltrom-
bopag aremore likely to complete antiviral therapy, leading to increased quality of
life and decreased future costs over a lifetime. More studies are needed to analyze
the safety of eltrombopag and to provide more accurate estimates of its effect on
platelet counts and patient withdrawal from antiviral therapy.
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OBJECTIVES: This study aimed to assess incremental cost-effectiveness of VMP vs
MPR-R in patients newly diagnosed with multiple myeloma (MM), ineligible for
ASCT, with average age of 70 years. METHODS: A Markov model from US payer’s
perspective was developed to assess cost-effectiveness of VMP vs MPR-R for treat-
ment of MM. The model included seven health states: responses (multiple), treat-
ment-free/maintenance, progression, second-line treatment, and death. Monthly
transition probabilities were estimated from patient-level data (VISTA) for VMP
andMP and frompublished data (MM-015) forMPR-R. Costs included drug,medical,
adverse event, second-line treatment, and resource utilization in 2010 US-dollar
value. State-specific utilities were derived from patient-level EQ-5D using US-spe-
cific weights. Effectiveness was expressed in LYs and QALYs. Costs and effective-
ness were discounted at 3%. ICER was calculated for VMP vs MPR-R over 20-year
horizon (lifetime). In the base case, the MPR-R vs MP hazard ratio (HR) for PFS was
0.499 and that for OS was 1, as the survival benefit with MPR-R vs MP was not
observed in MM-015. One-way sensitivity analyses were conducted for key param-
eters to assess the general robustness of themodel. RESULTS: Base-case results for
VMP vs.MPR-R showed: $119,102 vs $248,358 for directmedical costs; 4.187 years vs
3.409 years for LYs; cost of R maintenance was $107,047. VMP was associated with
reduced costs and better outcomes compared with MPR-R; VMP costs approxi-
mately 50% less than MPR-R and seems to provide slightly more QALYs (0.567) on
average. Sensitivity analyses supported the robustness ofmodel findings and iden-
tified the MPR-R vs MP HR for OS as a key driver; only when this HR was 0.24 did
MPR-R become cost-effective vs VMP at $100,000 per QALY. CONCLUSIONS: VMP
had lower costs and better health outcomes compared to MPR-R. R maintenance
showed little additional benefit.
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OBJECTIVES: Ankle sprain causes walking limitation, pain and consequently, eco-
nomic losses. The purpose of this study was to estimate the cost-effectiveness
from a societal perspective of sequential use of parecoxib/celecoxib for pain man-
agement associated with ankle sprain in adults. METHODS: A Markov model was
performed to estimate health and economic consequences during a time horizon
of 45 days (3-day cycles). Effectiveness measures were: percentage of patients re-
porting pain reduction, percentage of patients reporting50% pain reduction from
baseline, reduction of length of stay (LOS) and reduction in the number of treat-
ment retirements due adverse events. Transition probabilities were obtained from
a meta-analysis employing international published literature. Doses of compara-
tors were: diclofenac (75mg bid) followed by diclofenac (100mg bid); parecoxib
(40mg bid) followed by celecoxib (200mg bid) and ketorolac (30mg qid) followed by
ketorolac po (10mg tid) as the reference. Parenteral and oral forms were adminis-
tered for two and five days, respectively. Resource use was obtained from Social
SecurityMexican Institute databases (n1,395 records). Direct costswere extracted
from institutional official sources and indirect costs from a validated survey ap-
plied to patients. Costs included: hospitalization, drugs, medical procedures, im-
aging, adverse events management, disability benefits, productivity losses, and
out-of-pocket expenses. Probabilistic sensitivity analyseswere performed employ-
ing bootstrapping techniques. Acceptability curves were constructed. RESULTS:
Parecoxib/celecoxib, ketorolac and diclofenac costs per patient were: US$440.77
[95%CI US$425.65-US$455.88], US$526.08 [US$509.97-US$542.20] and US$815.43
[US$790.18-US$840.68], respectively (p0.05). Parecoxib/celecoxib exhibits the low-
est LOS (0.69 days [0.67–0.71] (p0.05)) and number of treatment discontinuations
(16/1000 patients). Acceptability curves showed that parecoxib/celecoxib will be
cost-effective with 90% of confidence at a willingness to pay closer to US$0.
CONCLUSIONS: Parecoxib/celecoxib is the less costly treatment to manage pain
associated with moderate ankle sprain in Mexico; as well it represents a cost-
saving alternative in LOS reduction and treatment discontinuation regarding com-
peting alternatives.
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OBJECTIVES:The treatment guidelines of obesity at theMexican Institute for Social
Security (IMSS) consider the pharmacological treatment together with the change
in health habits a proper option in cases of obese patients (BMI 30 kg/m2). With
the withdrawal of Sibutramine of the mexican market, Diethylpropion (Amfepra-
mone) emerge as a good candidate to fill the void of a scheme to control and reduce
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